The Company operates as a single reportable and operating segment focused on non-invasive coronary artery disease (CAD) detection solutions. The Chief Executive Officer, serving as the Chief Operating Decision Maker (CODM), reviews consolidated financial information, including revenue and net loss, to make operating decisions, allocate resources, and evaluate financial performance. Segment profit or loss is measured by consolidated net loss, which is used to assess actual results against expectations, establish performance metrics, and develop the annual budget. Key expenses within consolidated net loss include cost of revenue, research and development, and selling, general and administrative expenses, each detailed separately in the consolidated statements of operations and comprehensive loss. Additional expense items comprise interest income, interest expense, changes in fair value of warrant and derivative liabilities, loss on extinguishment of debt, other income (net), and provision for income taxes. Financial data for the years ended December 31, 2025, 2024, and 2023 include revenue, cost of revenue, research and development expenses (including regulatory and clinical), selling, general and administrative expenses (including sales and marketing), loss from operations, other income (expense), net, provision for income taxes, and segment net loss. The Company generates revenue and holds long-lived assets primarily in the United States.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
93.91 %